S.V. YAKOVLEVA^{1, 2}, I.YU. PIROGOVA¹

 ¹South Urals State Medical University, Chelyabinsk

²Medical Center «Lotos», Chelyabinsk

  Contact details:

Yakovleva S.V. — postgraduate student of the Department of Faculty Therapy, Head of the Department of Therapy

Address: 64 Vorovskogo St., Chelyabinsk, Russian Federation, 454092, tel.: +7-909-083-19-79, e-mail: ysv9090831979@gmail.com

 The purpose — to study the effect of vitamin D supplementation on the components of the metabolic syndrome, stage of steatosis and liver fibrosis in young men with and without non-alcoholic fatty liver disease (NAFLD).

Material and methods. The prospective study included 123 young male patients. Participants were divided into two groups: group I — persons with hepatic steatosis (n = 91), group II — persons without hepatic steatosis (n = 32). Patients in each group were divided into two subgroups (a and b): receiving (a) and not receiving (b) cholecalciferol. All persons who applied for an outpatient appointment underwent an anamnesis, measurement of blood pressure, assessment of anthropometric parameters, physical examination, biochemical analysis of blood on an empty stomach, and the level of 25(OH)D in blood serum was determined. The degreeы of steatosis and fibrosis were verified by liver elastometry.

Results. Analysis of vitamin D availability in young men showed the predominance of its deficiency in the group of men with NAFLD in comparison with their peers without liver pathology. The normal level of 25(OH)D against the background of hepatic steatosis was 7 times less common. With the normalization of the level of vitamin D in the group with NAFLD and reaching its level of 49.05 ng/ml, the level of fasting insulin, the HOMA-IR index, the level of AST, and the degree of liver steatosis reliably decreased. Upon reaching the level of vitamin D up to 52.8 ng/ml in persons without NAFLD, the level of fasting glucose and total cholesterol significantly decreased.

Conclusion. Timely detection of insufficient supply of vitamin D and its normalization in young men with NAFLD and in its absence allows implementing a strategy for the primary prevention of cardiovascular and metabolic diseases.

Key words: vitamin D, deficiency, young men, NAFLD.

REFERENCES

1. Evstifeeva S.E., Shal’nova S.A., Kutsenko V.A. et al. The prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (data from ESSE-RF-2). Kardiovaskulyarnaya terapiya i profilaktika, 2022,  no. 21,  pp. 40–49 (in Russ.). DOI: 10.15829/1728-8800-2022-3356
2. Younossi Z.M., Koenig A.B., Ricci F., Mantini C. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016,  vol. 64 (1),  pp. 73–84. DOI: 10.1002/hep.28431
3. Bisaccia G. et al. Nonalcoholic fatty liver disease and cardiovascular disease phenotype. Sage Open Medicine, 2020,  vol. 8,  pp. 1–15. DOI: 10.1177/2050312120933804
4. Maurice J., Manousou P. Non-alcoholic fatty liver disease. Clinical Medicine, 2018, vol. 18 (3),  pp. 245–250. DOI: 10.7861/clinmedicine.18-3-245
5. Xian Y.X., Weng J.P., Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chinese Medical Journal., 2020, vol. 134 (1),  pp. 8–19. DOI: 10.1097/CM9.0000000000001263
6. Després J.P., Cartier A., Côté M., Arsenault B.J. The concept of cardiometabolic risk: Bridging the fields of diabetology and cardiology. Ann of Med, 2008,  vol. 40,  pp. 514–523. DOI: 10.1080/07853890802004959
7. Than N.N., Newsome P.N. A concise review of non-alcoholic fatty liver disease. Atherosclerosis, 2015,  vol. 239 (1),  pp. 192–202. DOI: 10.1016/j.atherosclerosis.2015.01.001
8. Pirogova I.Yu., Yakovleva S.V., Shaimova I.S. et al. Factors associated with the formation and progression of steatosis and fibrosis in non-alcoholic fatty liver disease. Ural’skiy meditsinskiy zhurnal, 2019,  no. 8 (176),  pp. 30–36 (in Russ.). DOI: 10.25694/URMJ.2019.08.23
9. Mutt S.J., Jokelainen J., Sebert S. et al. Vitamin D Status and Components of Metabolic Syndrome in Older Subjects from Northern Finland (Latitude 65 North). Nutrients, 2019,  vol. 11 (6),  p. 1229. DOI: 10.3390/nu11061229
10. Zhang H., Shen Z., Lin Y. et al. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease. J Biol Chem., 2020, vol. 295 (12),  pp. 3891–3905. DOI: 10.1074/jbc.RA119.011487
11. Ivashkin V.T., Drapkina O.M., Maev I.V. et al. The prevalence of non-alcoholic fatty liver disease in outpatients in the Russian Federation: results of the DIREG 2 study. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2015,  no. 6,  pp. 31–41 (in Russ.).
12. Zhai H.L., Wang N.J., Han B. et al. Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: a cross-sectional study (Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China)). Br J Nutr, 2016,  vol. 115 (8),  pp. 1352–1359. DOI: 10.1017/S0007114516000386
13. Walsh J.S., Bowles S., Evans A.L. Vitamin D in obesity. Curr Opin Endocrinol Diabetes Obes, 2017,  vol. 24 (6),  pp. 389–394. DOI: 10.1097/MED.0000000000000371
14. Vranić L., Mikolašević I., Milić S. Vitamin D Deficiency: Consequence or Cause of Obesity? Medicina (Kaunas), 2019,  vol. 55 (9),  pp. 541. DOI: 10.3390/medicina55090541
15. Nicholls D.G. The Pancreatic β-Cell: A Bioenergetic Perspective. Physiol Rev, 2016, vol. 96 (4),  pp. 1385–1447. DOI: 10.1152/physrev.00009.2016
16. Szymczak-Pajor I., Śliwińska A. Analysis of Association between Vitamin D Deficiency and Insulin Resistance. Nutrients, 2019,  vol. 11 (4),  p. 794. DOI: 10.3390/nu11040794
17. Fujii H., Kawada N. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease, Japan Study Group Of Nafld Jsg-Nafld. Int J Mol Sci, 2020,  vol. 21 (11), pp. 3863. DOI: 10.3390/ijms21113863